Drug Profile
Reteplase biosimilar - Shanghai Fudan-Zhangjiang/Shandong Ahua
Alternative Names: r-tPA - Shanghai Fudan-Zhangjiang/Shandong Ahua; Recombinant tissue plasminogen activator derivative - Shanghai Fudan-Zhangjiang/Shandong Ahua; Rui Tong LiLatest Information Update: 23 May 2015
Price :
$50
*
At a glance
- Originator Shanghai Fudan-Zhangjiang Bio-Pharmaceutical
- Developer Shandong Ahua Biochemical
- Class Plasminogen activator enzymes; Recombinant proteins; Thrombolytics; Vascular disorder therapies
- Mechanism of Action Plasminogen activators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Myocardial infarction